

Srihari S Naidu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11607766/publications.pdf>

Version: 2024-02-01

107
papers

7,659
citations

126901

33
h-index

51602

86
g-index

110
all docs

110
docs citations

110
times ranked

7661
citing authors

#	ARTICLE	IF	CITATIONS
1	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2011, 124, e783-831.	1.6	1,039
2	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2011, 58, e212-e260.	2.8	984
3	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. <i>Circulation</i> , 2011, 124, 2761-2796.	1.6	725
4	SCAI clinical expert consensus statement on the classification of cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 29-37.	1.7	657
5	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care. <i>Journal of the American College of Cardiology</i> , 2015, 65, e7-e26.	2.8	491
6	The Current Use of Impella 2.5 in Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results from the USpella Registry. <i>Journal of Interventional Cardiology</i> , 2014, 27, 1-11.	1.2	316
7	Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2117-2128.	2.8	314
8	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, e153-e203.	0.8	260
9	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2703-2738.	2.8	252
10	Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy. <i>JAMA Cardiology</i> , 2016, 1, 324.	6.1	228
11	SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies. <i>Journal of the American College of Cardiology</i> , 2022, 79, 933-946.	2.8	214
12	Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: The USpella Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 717-725.	1.7	129
13	Novel Percutaneous Cardiac Assist Devices. <i>Circulation</i> , 2011, 123, 533-543.	1.6	118
14	Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. <i>Journal of the American College of Cardiology</i> , 2022, 80, 95-108.	2.8	118
15	Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2003, 92, 1160-1164.	1.6	108
16	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the Tj ETQq0 0 0 rgBT /Overlock 10 T	1.7	108
17	COVID-19 Pandemic: Cardiovascular Complications and Future Implications. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 311-324.	2.2	98
18	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, e5-e23.	0.8	97

#	ARTICLE	IF	CITATIONS
19	Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 586-597.	1.7	89
20	Contemporary Incidence and Predictors of Stent Thrombosis and Other Major Adverse Cardiac Events in the Year After XIENCE V Implantation. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 626-635.	2.9	86
21	The science behind percutaneous hemodynamic support: A review and comparison of support strategies. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 816-829.	1.7	82
22	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2140-2141.	2.8	78
23	SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia) <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 407-423.	1.7	78
24	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 1303-1338.	0.8	73
25	SCAI shock classification in acute myocardial infarction: Insights from the National Cardiogenic Shock Initiative. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1137-1142.	1.7	68
26	Clinical expert consensus statement on best practices in the cardiac catheterization laboratory: Society for cardiovascular angiography and interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 456-464.	1.7	56
27	The State of the Absorb Bioresorbable Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2349-2359.	2.9	55
28	Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 352-357.	1.7	53
29	Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients. <i>American Heart Journal</i> , 2020, 219, 37-46.	2.7	48
30	Transcatheter Device Closure of Interatrial Septal Defects in Patients with Hypoxia. <i>Journal of Interventional Cardiology</i> , 2005, 18, 227-232.	1.2	42
31	Sex Differences in Outcomes Following Percutaneous Coronary Intervention According to Age. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, S16-25.	2.2	41
32	Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: Insights from the PROTECT II study. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 1057-1064.	1.7	40
33	Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients. <i>Circulation: Heart Failure</i> , 2021, 14, e007678.	3.9	38
34	Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. <i>American Heart Journal</i> , 2021, 239, 80-89.	2.7	35
35	Evaluating the learning curve in the prospective Randomized Clinical Trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: a prespecified subanalysis of the PROTECT II study. <i>American Heart Journal</i> , 2014, 167, 472-479.e5.	2.7	34
36	SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E233-E247.	1.7	32

#	ARTICLE	IF	CITATIONS
37	Risk of Death and Myocardial Infarction in Patients With Peripheral Arterial Disease Undergoing Percutaneous Coronary Intervention (from the National Heart, Lung and Blood Institute Dynamic Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	27
38	SCAI expert consensus update on best practices in the cardiac catheterization laboratory. Catheterization and Cardiovascular Interventions, 2021, 98, 255-276.	1.7	27
39	2015 SCAI/HFSA/ACC clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care (Endorsed by the American heart association, the Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	25
40	Contemporary Incidence and Predictors of Major Adverse Cardiac Events After Saphenous Vein Graft Intervention With Embolic Protection (an AMETHYST Trial Substudy). American Journal of Cardiology, 2010, 105, 1060-1064.	1.6	18
41	Evaluation and Management of Concomitant Hypertrophic Obstructive Cardiomyopathy and Valvular Aortic Stenosis. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 17.	0.9	13
42	Left Ventricular Assist Device Implantation in Hypertrophic and Restrictive Cardiomyopathy: A Systematic Review. ASAIO Journal, 2021, 67, 239-244.	1.6	13
43	Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. International Journal of Cardiology, 2017, 229, 82-89.	1.7	12
44	Current Status and Future Perspectives on Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. Current Cardiology Reports, 2014, 16, 478.	2.9	11
45	Executive Summary of the SCAI/HFSA Clinical Expert Consensus Document on the Use of Invasive Hemodynamics for the Diagnosis and Management of Cardiovascular Disease. Journal of Cardiac Failure, 2017, 23, 487-491.	1.7	11
46	Novel Pharmacotherapy in Hypertrophic Cardiomyopathy. Cardiology in Review, 2018, 26, 239-244.	1.4	11
47	Myosin Modulation in Hypertrophic Cardiomyopathy and Systolic Heart Failure: Getting Inside the Engine. Circulation, 2021, 144, 759-762.	1.6	11
48	Outcome of Percutaneous Coronary Intervention in Unstable Angina Pectoris Versus Stable Angina Pectoris in Two Different Time Periods. American Journal of Cardiology, 2006, 98, 447-452.	1.6	10
49	2015 <scps>SCAI</scps>/<scps>ACC</scps>/<scps>HFSA</scps>/<scps>SIS</scps> clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in Cardiovascular Care (Endorsed by the American heart association, the Cardiological society of India, and Sociedad Latino) Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	10
50	Readmission following urgent transcatheter aortic valve implantation versus urgent balloon aortic valvuloplasty in patients with decompensated heart failure or cardiogenic shock. Catheterization and Cardiovascular Interventions, 2021, 98, 607-612.	1.7	9
51	Sex Differences in the Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy. JACC: Cardiovascular Interventions, 2021, 14, 930-932.	2.9	9
52	SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies. , 2022, 1, 100008.		8
53	Novel intracoronary steerable support catheter for complex coronary intervention. Journal of Invasive Cardiology, 2006, 18, 80-1.	0.4	8
54	Usefulness of noncoronary vascular disease in predicting adverse events in the year following percutaneous coronary intervention. American Journal of Cardiology, 2005, 95, 575-580.	1.6	7

#	ARTICLE	IF	CITATIONS
55	Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIa inhibitors: A meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 364-375.	1.7	7
56	Percutaneous Mitral Valve Repair versus Optimal Medical Therapy in Patients with Functional Mitral Regurgitation: A Systematic Review and Meta-Analysis. <i>Journal of Interventional Cardiology</i> , 2019, 2019, 1-10.	1.2	7
57	Social Media as a Tool to Advance Women in Cardiology: Paving the Way for Gender Equality and Diversity. <i>CJC Open</i> , 2021, 3, S130-S136.	1.5	7
58	Performance Volume Thresholds for Alcohol Septal Ablation in Treating Hypertrophic Cardiomyopathy: Guidelines, Competency Statements, and Now Data. <i>Canadian Journal of Cardiology</i> , 2018, 34, 13-15.	1.7	6
59	Historical Perspectives in the Evolution of Hypertrophic Cardiomyopathy. <i>Cardiology Clinics</i> , 2019, 37, 1-10.	2.2	6
60	Effect of Gender and Race on Outcomes in Dialysis-Dependent Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2011, 107, 1319-1323.	1.6	5
61	Trends in the Use of Short-Term Mechanical Circulatory Support in the United States – An Analysis of the 2012 – 2015 National Inpatient Sample. <i>Structural Heart</i> , 2019, 3, 499-506.	0.6	5
62	Utilization Rates of Diagnostic and Therapeutic Vascular Procedures Among Patients Undergoing Lower Extremity Amputations in a Rural Community Hospital: A Clinicopathological Correlation. <i>Vascular and Endovascular Surgery</i> , 2021, 55, 325-331.	0.7	5
63	Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2022, 7, 5-23.	1.0	5
64	Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study. <i>Cardiology and Therapy</i> , 2022, 11, 249-267.	2.6	5
65	Executive summary of the SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1294-1299.	1.7	4
66	Long-Term Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in End-Stage Renal Disease Patients on Dialysis. <i>Cardiology in Review</i> , 2018, 26, 277-286.	1.4	4
67	Cardiac implantable electronic device placement following alcohol septal ablation for hypertrophic cardiomyopathy in the United States. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2712-2719.	1.7	4
68	Acute myocardial infarction in the young with diabetes mellitus- national inpatient sample study with sex-based difference in outcomes. <i>International Journal of Cardiology</i> , 2021, 326, 35-41.	1.7	4
69	Cardiac arrest in spontaneous subarachnoid hemorrhage and associated outcomes. <i>Neurosurgical Focus</i> , 2022, 52, E6.	2.3	4
70	Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument. <i>PharmacoEconomics - Open</i> , 2022, 6, 563-574.	1.8	4
71	Survival and Pacemaker Risk After Alcohol Septal Ablation: Informing the Choice of Invasive Therapy for Hypertrophic Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1369-1370.	1.7	3
72	Hemodynamic Support Devices for Complex Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2016, 5, 187-200.	0.4	3

#	ARTICLE	IF	CITATIONS
73	“Should SCAI update its position on the role of Public Reporting?” Catheterization and Cardiovascular Interventions, 2019, 93, 448-450.	1.7	3
74	Hypertrophic Cardiomyopathy: Mastering the Multiple Facets of a Complex Disease. Cardiology Clinics, 2019, 37, ix-x.	2.2	3
75	Impact of Pulmonary Hypertension on In-Hospital Outcomes and 30-Day Readmissions Following Percutaneous Coronary Interventions. Mayo Clinic Proceedings, 2021, 96, 2058-2066.	3.0	3
76	A haemodynamic conundrum: a case report of a patient with concurrent pulmonary arterial hypertension and hypertrophic obstructive cardiomyopathy. European Heart Journal - Case Reports, 2021, 5, ytab354.	0.6	3
77	Unprotected left main “kissing” stent implantation with a percutaneous ventricular assist device. Journal of Invasive Cardiology, 2004, 16, 683-4.	0.4	3
78	Alcohol septal ablation for failed surgical myectomy. Journal of Invasive Cardiology, 2005, 17, 569-71.	0.4	3
79	Does relief of outflow tract obstruction in patients with hypertrophic cardiomyopathy improve long-term survival? Implications for lowering the threshold for surgical myectomy and alcohol septal ablation. Annals of Translational Medicine, 2016, 4, 485-485.	1.7	2
80	Investing in our future: Update on the SCAI Emerging Leader Mentorship (ELM) Program. Catheterization and Cardiovascular Interventions, 2016, 88, 674-677.	1.7	2
81	SCAI position statement concerning coverage policies for percutaneous coronary interventions based on the appropriate use criteria. Catheterization and Cardiovascular Interventions, 2016, 87, 1127-1129.	1.7	2
82	“How can SCAI and industry partners increase adherence and educate interventionalists on optimal medical therapy?” Catheterization and Cardiovascular Interventions, 2019, 93, 305-308.	1.7	2
83	SCAI 2018 Think Tank Proceedings: “What should the role of the surgeon be in TAVR, both as a co-operator and in patient evaluation for TAVR?”. Catheterization and Cardiovascular Interventions, 2019, 93, 178-179.	1.7	2
84	The declining relevance of age in the treatment of atrial septal defects. Journal of Invasive Cardiology, 2008, 20, 177-8.	0.4	2
85	Three years since the FDA advisory panel on drug-eluting stents: what have we learned about off-label use and stent thrombosis?. Journal of Invasive Cardiology, 2010, 22, 20-1.	0.4	2
86	Strength training and cardiovascular health: A meta-analysis. Progress in Cardiovascular Diseases, 2022, 73, 85-87.	3.1	2
87	Key Concepts Surrounding Cardiogenic Shock. Current Problems in Cardiology, 2022, 47, 101303.	2.4	2
88	Impact of intraprocedural thrombotic events on short- and long-term outcomes following percutaneous coronary intervention. Evidence from a meta-analysis. International Journal of Cardiology, 2016, 202, 469-476.	1.7	1
89	Interventional therapies for relief of obstruction in hypertrophic cardiomyopathy: discussion and proposed clinical algorithm. Hospital Practice (1995), 2018, 46, 58-63.	1.0	1
90	Role of Advanced Testing. Cardiology Clinics, 2019, 37, 73-82.	2.2	1

#	ARTICLE	IF	CITATIONS
91	Characteristics and hospital outcomes of coronary atherectomy within the United States: a multivariate and propensity-score matched analysis. Expert Review of Cardiovascular Therapy, 2021, 19, 865-870.	1.5	1
92	Indications for and Individualization of Septal Reduction Therapy. , 2015, , 207-222.		1
93	Here comes the sun: physician relationships with industry and the Sunshine Act. Journal of Invasive Cardiology, 2014, 26, 228.	0.4	1
94	Interventional Therapies for Heart Failure in the Elderly. Clinics in Geriatric Medicine, 2007, 23, 155-178.	2.6	0
95	Interventional Therapies for Heart Failure in the Elderly. Heart Failure Clinics, 2007, 3, 485-500.	2.1	0
96	Operationalizing Interventional Heart Failure: Adding Substance to the Concept. Interventional Cardiology Clinics, 2017, 6, xiii-xiv.	0.4	0
97	Pharmacological and non-pharmacological treatment of obstructive hypertrophic cardiomyopathy. Expert Review of Cardiovascular Therapy, 2018, 16, 21-26.	1.5	0
98	Indications for and Individualization of Septal Reduction Therapy. , 2019, , 305-323.		0
99	Longitudinal Case-Based Presentations in HCM. , 2019, , 429-468.		0
100	How to assess the severity of heart failure?. Current Opinion in Critical Care, 2020, Publish Ahead of Print, 386-391.	3.2	0
101	Longitudinal Case Based Presentations in HCM. , 2015, , 287-321.		0
102	Rethinking the selection criteria for alcohol septal ablation - is it time to push the envelope?. Journal of Invasive Cardiology, 2010, 22, 592-3.	0.4	0
103	Protecting the doctor-patient relationship. Journal of Invasive Cardiology, 2012, 24, 3 p following E158.	0.4	0
104	Outcomes, Temporal Trends, and Resource Utilization in Ischemic versus Nonischemic Cardiogenic Shock. Critical Pathways in Cardiology, 2022, 21, 11-17.	0.5	0
105	Conversations in cardiology: Late career transitionsâ€”Retool, retire, refocus. Catheterization and Cardiovascular Interventions, 2022, 99, 2136-2144.	1.7	0
106	A Comparison of In-Hospital Outcomes Between the Use of Impella and IABP in Acute Myocardial Infarction Cardiogenic Shock Undergoing Percutaneous Coronary Intervention.. Journal of Invasive Cardiology, 2022, 34, E98-E103.	0.4	0
107	Meta-Analysis of Brief Dual-Antiplatelet Therapy Duration After Percutaneous Coronary Intervention. American Journal of Cardiology, 2022, , .	1.6	0